Curis, Inc. (CRIS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Analysis Summary
Curis, Inc. reported revenue of $9.4M in the most recent fiscal year, growing at a 5-year CAGR of -2.7%.
Trailing-twelve-month margins: gross margin 99.3%, operating margin -8.3%, net margin -490.3%.
At the current price of $1.12, CRIS has negative trailing earnings (P/E not meaningful) and an ROE of -10.35%. Market capitalisation stands at $2M.
Balance sheet quality for CRIS: current ratio of 0.5, net cash position of $3.4M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1035.26% |
| Return on Invested Capital | -567.17% |
| Return on Assets | -111.51% |
| Gross Margin | 99.28% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 0.49 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -92.32 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRIS | Curis, Inc. | $2M | 0.48 | -10.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -34.12% |
| 3 months | -86.70% |
| Year-to-date | -94.33% |
| 1 year | -96.65% |
| 3 years | -99.40% |
| 5 years | -99.97% |
52-Week Range
| 52-week High | $35.80 |
| 52-week Low | $1.07 |
| Avg Volume (90d) | 215K |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks